These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36339622)

  • 1. Patient-reported outcomes labeling for oncology drugs: Multidisciplinary perspectives on current status and future directions.
    Cella D; Chen CI; Quek RGW; Uribarren A; Reaney M; Mastey V; Collyar D; Chassany O
    Front Pharmacol; 2022; 13():1031992. PubMed ID: 36339622
    [No Abstract]   [Full Text] [Related]  

  • 2. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
    Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
    Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review of Labeling Based on Patient-Reported Outcome Endpoints for New Oncology Drugs Approved by the European Medicines Agency (2017-2021).
    Gnanasakthy A; Levy C; Norcross L; Doward L; Winnette R
    Value Health; 2023 Jun; 26(6):893-901. PubMed ID: 36746305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes in breast cancer FDA drug labels and review documents.
    Hong K; Majercak KR; Villalonga-Olives E; Perfetto EM
    J Patient Rep Outcomes; 2021 Apr; 5(1):36. PubMed ID: 33881661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of patient-reported outcomes in the approval of novel oncology drugs in the United States, 2017-2022.
    Ge C; Guo K; Li Y; Li G; Zhang H; Yang J; Liu Y; Yin C; Liu S; Xie S; Chen X
    EClinicalMedicine; 2023 May; 59():101953. PubMed ID: 37089618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes in vaccines research: relevance for decision-making.
    Curran D; Cabrera ES; Nelsen L
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-8. PubMed ID: 33606595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency.
    Bottomley A; Jones D; Claassens L
    Eur J Cancer; 2009 Feb; 45(3):347-53. PubMed ID: 19013787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010).
    DeMuro C; Clark M; Doward L; Evans E; Mordin M; Gnanasakthy A
    Value Health; 2013 Dec; 16(8):1150-5. PubMed ID: 24326168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels.
    Willke RJ; Burke LB; Erickson P
    Control Clin Trials; 2004 Dec; 25(6):535-52. PubMed ID: 15588741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient Reported Outcome (PRO) assessment in epilepsy: a review of epilepsy-specific PROs according to the Food and Drug Administration (FDA) regulatory requirements.
    Nixon A; Kerr C; Breheny K; Wild D
    Health Qual Life Outcomes; 2013 Mar; 11():38. PubMed ID: 23497117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001.
    Acquadro C; Berzon R; Dubois D; Leidy NK; Marquis P; Revicki D; Rothman M;
    Value Health; 2003; 6(5):522-31. PubMed ID: 14627058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014).
    Gnanasakthy A; DeMuro C; Clark M; Haydysch E; Ma E; Bonthapally V
    J Clin Oncol; 2016 Jun; 34(16):1928-34. PubMed ID: 27069082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium guidance.
    Banerjee AK; Okun S; Edwards IR; Wicks P; Smith MY; Mayall SJ; Flamion B; Cleeland C; Basch E;
    Drug Saf; 2013 Dec; 36(12):1129-49. PubMed ID: 24092596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers.
    Zagadailov E; Fine M; Shields A
    Am Health Drug Benefits; 2013 Jul; 6(5):264-74. PubMed ID: 24991362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 15 Year Review (2006-2020) of Patient-Reported Outcome (PRO) in United States Oncology Product Labeling and Trends in Sponsor Size and Oncology Experience.
    Cooper L; Wo E; Lee I
    Arch Intern Med Res; 2022; 5(3):412-419. PubMed ID: 37065859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels.
    Gondek K; Sagnier PP; Gilchrist K; Woolley JM
    J Clin Oncol; 2007 Nov; 25(32):5087-93. PubMed ID: 17991926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comparison of Seven Oncology External Control Arm Case Studies: Critiques From Regulatory and Health Technology Assessment Agencies.
    Jaksa A; Louder A; Maksymiuk C; Vondeling GT; Martin L; Gatto N; Richards E; Yver A; Rosenlund M
    Value Health; 2022 Dec; 25(12):1967-1976. PubMed ID: 35760714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs.
    Zeukeng MJ; Seoane-Vazquez E; Bonnabry P
    Eur J Clin Pharmacol; 2018 Jun; 74(6):811-818. PubMed ID: 29470610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020.
    Teixeira MM; Borges FC; Ferreira PS; Rocha J; Sepodes B; Torre C
    Front Med (Lausanne); 2022; 9():968272. PubMed ID: 36035431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.